Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups

Inflammatory Bowel Diseases

Volumn 18, Issue 12, 2012, Pages 2294-2300

  Cheifetz, A S ^a   Melmed, G Y ^b   Spiegel, B ^c   Talley, J ^d   Devlin, S M ^e   Raffals, L ^f   Irving, P M ^g   Jones, J ^h   Kaplan, G G ^e   Kozuch, P ⁱ   Sparrow, M ^j   Velayos, F ^k   Baidoo, L ^l   Bressler, B ^m   Siegel, C A ⁿ  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f MAYO CLINIC   (United States)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF SASKATCHEWAN   (Canada)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j ALFRED HOSPITAL   (Australia)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

more..

Author keywords

comparative effective research; Crohn's disease; ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DISEASE MARKER; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT CARE; PRIORITY JOURNAL; TREATMENT PLANNING; ULCERATIVE COLITIS;

ADULT; AGED; COMPARATIVE EFFECTIVENESS RESEARCH; DATA COLLECTION; FEMALE; FOCUS GROUPS; HEALTH PERSONNEL; HEALTH PRIORITIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84869215755     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22920     Document Type: Article

References (9)

1. Ratner R, Eden J, Wolman D, Greenfield S, Sox H, eds. Initial national priorities for comparative effectiveness research. In:, Medicine Io, ed. Washington DC: National Academies Press; 2009.
2. Sox HC, Greenfield S,. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009; 151: 203-205.
3. Siegel CA,. Accidentally ASCENDing into comparative effective research for inflammatory bowel disease. Gastroenterology. 2009; 137: 1880-1882.
4. Ericsson KaSH,. Protocol Analysis: Verbal Reports as Data (Revised Edition). Cambridge, MA: MIT Press, 1993.
5. DeWalt DA, Rothrock N, Yount S, et al. Evaluation of item candidates: the PROMIS qualitative item review. Med Care. 2007; 45: S12-21.
6. Brook R,. The RAND/UCLA Appropriateness Method. Clinical Practice Guideline Development: Methodology Perspectives. Rockville, MD: AHCR; 1994.
7. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
8. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-887.
9. Slattery E, Harewood GC,. Comparative effectiveness research in inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17: E46-47.